-transparent.png){kind=logo}
The complete response (CR) rate of disseminated germ-cell tumors with current aggressive chemotherapy and surgical resection of localized residual disease is between 70%-80%. Most patients who relapse do so within the first year of therapy. We have observed seven patients with germ-cell tumors treated with a variety of modalities who relapsed after more than two years in CR (45-87 months). Five patients are alive after salvage therapy with follow-up too short to assess the durability of second remission. There were no features distinguishing late relapse patients from all patients treated with chemotherapy for germ-cell tumors. Follow-up in patients treated for germ-cell tumors with chemotherapy should be extended to five years before curability can be established.
H R Terebelo, and
H G Taylor, and
A Brown, and
N Martin, and
F H Stutz, and
J Blom, and
L Geier
April 2004,
World journal of urology,
H R Terebelo, and
H G Taylor, and
A Brown, and
N Martin, and
F H Stutz, and
J Blom, and
L Geier
May 1995,
Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
H R Terebelo, and
H G Taylor, and
A Brown, and
N Martin, and
F H Stutz, and
J Blom, and
L Geier
May 1983,
Lancet (London, England),
H R Terebelo, and
H G Taylor, and
A Brown, and
N Martin, and
F H Stutz, and
J Blom, and
L Geier
October 1995,
The Journal of urology,
H R Terebelo, and
H G Taylor, and
A Brown, and
N Martin, and
F H Stutz, and
J Blom, and
L Geier
April 2024,
Oncology (Williston Park, N.Y.),
H R Terebelo, and
H G Taylor, and
A Brown, and
N Martin, and
F H Stutz, and
J Blom, and
L Geier
November 2006,
Journal of the National Comprehensive Cancer Network : JNCCN,
H R Terebelo, and
H G Taylor, and
A Brown, and
N Martin, and
F H Stutz, and
J Blom, and
L Geier
May 1986,
Lancet (London, England),
H R Terebelo, and
H G Taylor, and
A Brown, and
N Martin, and
F H Stutz, and
J Blom, and
L Geier
August 1990,
The New England journal of medicine,
H R Terebelo, and
H G Taylor, and
A Brown, and
N Martin, and
F H Stutz, and
J Blom, and
L Geier
August 2015,
The Urologic clinics of North America,
H R Terebelo, and
H G Taylor, and
A Brown, and
N Martin, and
F H Stutz, and
J Blom, and
L Geier
January 2005,
Urologic oncology,
